These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 22369284)

  • 1. Rituximab for chronic lymphocytic leukemia.
    Robak T
    Expert Opin Biol Ther; 2012 Apr; 12(4):503-15. PubMed ID: 22369284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging immunological drugs for chronic lymphocytic leukemia.
    Robak P; Smolewski P; Robak T
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):423-47. PubMed ID: 26153226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
    Griffin MM; Morley N
    Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia.
    Dretzke J; Barton P; Kaambwa B; Connock M; Uthman O; Bayliss S; Meads C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):19-26. PubMed ID: 21047487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
    Lin TS; Moran M; Lucas M; Waymer S; Jefferson S; Fischer DB; Grever MR; Byrd JC
    Hematol Oncol Clin North Am; 2004 Aug; 18(4):895-913, ix-x. PubMed ID: 15325705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide in lymphomas and chronic lymphocytic leukemia.
    Wiernik PH
    Expert Opin Pharmacother; 2013 Mar; 14(4):475-88. PubMed ID: 23356486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
    J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):70-4. PubMed ID: 11842391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in chronic lymphocytic leukemia.
    Jaglowski SM; Byrd JC
    Semin Hematol; 2010 Apr; 47(2):156-69. PubMed ID: 20350663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.
    Jain P; O'Brien S
    Expert Opin Biol Ther; 2013 Feb; 13(2):169-82. PubMed ID: 23256681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in chronic lymphocytic leukemia.
    James DF; Kipps TJ
    Adv Ther; 2011 Jul; 28(7):534-54. PubMed ID: 21725721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.
    Korycka-Wołowiec A; Wołowiec D; Robak T
    Expert Opin Drug Saf; 2015; 14(12):1945-59. PubMed ID: 26566719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.
    Lepretre S; Jäger U; Janssens A; Leblond V; Nikitin E; Robak T; Wendtner CM
    Leuk Lymphoma; 2012 May; 53(5):820-9. PubMed ID: 21992675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
    Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
    Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia.
    Hus I; Salomon-Perzyński A; Robak T
    Expert Opin Biol Ther; 2020 Jul; 20(7):799-812. PubMed ID: 32090643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.
    Klepfish A; Gilles L; Ioannis K; Rachmilewitz EA; Schattner A
    Ann N Y Acad Sci; 2009 Sep; 1173():865-73. PubMed ID: 19758239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Cvetković RS; Perry CM
    Drugs; 2006; 66(6):791-820. PubMed ID: 16706552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.